Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Multiple Myeloma 10Neoplasms 6Lymphoma, Non-Hodgkin 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 4Lymphoma 4Leukemia 4Hodgkin Disease 4Burkitt Lymphoma 4Breast Neoplasms 4Vomiting 3Prostatic Neoplasms 3Lymphoma, B-Cell 3Lung Neoplasms 3Leukemia, Hairy Cell 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomatitis 2Stomach Neoplasms 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Myelodysplastic Syndromes 2Mucositis 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Diphenhydramine × Clear all
NCT04165096 2026-05-13

MK-3475-01C

Merck Sharp & Dohme LLC

Phase 2 Completed
128 enrolled 14 charts
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Not yet recruiting
430 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01455389 2022-03-02

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Genprex, Inc.

Phase 1/2 Terminated
25 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡